证券代码：300871 证券简称：回盛生物 公告编号：2025-100 武汉回盛生物科技股份有限公司 关于2025年前三季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本次计提资产减值准备情况概述 （一）计提资产减值准备原因 根据《企业会计准则》及武汉回盛生物科技股份有限公司（以下简称"公 司"）会计政策、会计估计等相关规定，基于谨慎性原则，为客观、公允地反 映公司财务状况、资产价值和经营成果，公司对合并报表范围内截至 2025 年 9 月 30 日可能发生信用及资产减值损失的有关资产进行了减值测试，并对有 关资产减值的可能性进行了充分的评估和分析，计提了信用及资产减值准备。 （二）计提减值准备的资产范围和金额 | | 资产减值项目 | 本期发生金额 | | --- | --- | --- | | | 应收账款减值损失 | -484.18 | | 1.信用减值损失 | 其他应收款坏账损失 | 60.80 | | | 小计 | -423.38 | | | 存货跌价损失及合同履约成本减值损失 | -192.40 | | 2.资产减值 ...

证券代码：300871 证券简称：回盛生物 公告编号：2025-098 武汉回盛生物科技股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉回盛生物科技股份有限公司（以下简称"公司"）第四届董事会第二 次会议于 2025 年 10 月 27 日在公司会议室以现场结合通讯方式召开，本次会 议通知于 2025 年 10 月 24 日以电子邮件及电话方式送达全体董事。本次应出 席董事 5 名，实际出席会议的董事 5 名，其中以通讯方式出席的董事 1 名。本 次会议由董事长张卫元先生主持，公司高级管理人员列席了本次会议，会议的 召集、召开和表决程序符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，通过了以下议案： （一）审议通过了《关于<2025 年第三季度报告>的议案》 公司董事会在全面审核《2025 年第三季度报告》后，一致认为：公司 2025 年第三季度报告编制和审核的程序符合相关法律法规，报告内容真实、准确、 完整地反映了公司 ...

Core Insights - The animal health sector experienced a rise of 1.56% on October 27, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance Summary - Huisheng Biological (300871) closed at 21.69, up 4.53% with a trading volume of 105,300 shares and a turnover of 227 million yuan [1] - Xianfeng Holdings (002141) closed at 4.05, up 3.32% with a trading volume of 503,300 shares and a turnover of 203 million yuan [1] - Biological Shares (600201) closed at 11.08, up 2.88% with a trading volume of 444,500 shares and a turnover of 489 million yuan [1] - Other notable stocks include Shunlian Biological (688098) at 11.00, up 2.33%, and Ruipu Biological (300119) at 21.33, up 2.20% [1] Capital Flow Analysis - The animal health sector saw a net inflow of 91.28 million yuan from institutional investors, while retail investors experienced a net outflow of 1.02 billion yuan [2] - Major stocks like Biological Shares (600201) had a net inflow of 64.91 million yuan from institutional investors, while Huisheng Biological (300871) saw a net inflow of 24.29 million yuan [3] - Conversely, *ST Green Kang (002868) experienced a significant net outflow of 4.93 million yuan from institutional investors [3]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥437,334,051.69, representing a year-on-year increase of 22.76%[5] - The net profit attributable to shareholders for the same period was ¥70,724,741.75, a significant increase of 1,575.79% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥66,546,036.62, reflecting a 921.83% increase year-on-year[5] - The company reported a net profit of ¥188,484,725.84 for the first nine months of 2025, a 495.84% increase year-on-year[12] - Net profit for the current period was ¥188,484,725.84, compared to a net loss of ¥47,615,990.17 in the previous period, indicating a turnaround in profitability[24] - Earnings per share (EPS) for the current period was ¥1.0134, compared to a loss per share of ¥0.2874 in the previous period[25] - The company reported a total comprehensive income of ¥186,173,900.97, compared to a loss of ¥48,383,298.05 in the previous period[25] Assets and Liabilities - The total assets as of September 30, 2025, were ¥2,958,011,760.44, showing a decrease of 1.88% from the end of the previous year[5] - The company's total assets decreased from 3,014,682,865.02 yuan at the beginning of the period to 2,958,011,760.44 yuan at the end of the period, a reduction of approximately 1.87%[20] - The total liabilities decreased from 1,549,479,748.16 yuan to 839,938,116.60 yuan, a reduction of about 45.8%[20] - The total liabilities amounted to ¥839,938,116.60, while total equity reached ¥2,118,073,643.84, indicating a strong balance sheet[21] Cash Flow - The cash flow from operating activities for the year-to-date reached ¥181,515,060.75, a remarkable increase of 2,452.72%[5] - Cash inflow from operating activities totaled ¥991,584,938.53, an increase from ¥727,679,278.47 in the previous period[26] - The net cash flow from operating activities was $181,515,060.75, a significant increase from $7,110,643.63 in the previous period, indicating strong operational performance[27] - Cash outflows from investing activities totaled $639,792,156.12, compared to $659,840,673.74 in the prior period, reflecting a decrease in investment expenditures[27] - The net cash flow from financing activities was -$68,052,667.23, a decline from a positive cash flow of $29,649,582.00 in the previous period, suggesting increased financial strain[27] - The total cash and cash equivalents at the end of the period amounted to $152,827,248.69, up from $139,349,768.58 in the previous period, indicating improved liquidity[27] Shareholder Information - The largest shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 40.92% of the shares, totaling 82,800,000 shares[16] - The company has a share repurchase account holding 753,600 shares, representing 0.37% of total shares[16] Research and Development - Research and development expenses for the first nine months of 2025 amounted to ¥54,023,597.12, up 38.69% from the same period last year[12] - Research and development expenses increased to ¥54,023,597.12 from ¥38,952,745.03, highlighting the company's commitment to innovation[24] Operational Efficiency - The weighted average return on equity for the year-to-date was 10.35%, an increase of 13.57% compared to the previous year[5] - The company experienced a 606.40% increase in tax payable, amounting to ¥19,924,558.62, primarily due to increased income tax obligations[10] - The company's cash flow from operating activities showed resilience despite overall cash flow challenges, reflecting operational efficiency improvements[27] Inventory and Receivables - The company's inventory increased from 248,164,158.72 yuan to 254,459,287.83 yuan, an increase of about 2.5%[19] - Accounts receivable rose from 368,367,475.80 yuan to 391,468,700.00 yuan, an increase of approximately 6.3%[18] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]

回盛生物公告，第三季度营收为4.37亿元，同比增长22.76%；净利润为7072.47万元，同比增长 1,575.79%。前三季度营收为12.6亿元，同比增长58.92%；净利润为1.88亿元，同比增长494.28%。 ...

Core Insights - The implementation of the integrated raw material and formulation strategy has significantly enhanced the company's competitiveness and profitability [2] - The company's active pharmaceutical ingredient (API) business revenue saw substantial growth compared to the same period last year [2] - The company is increasing its investment in microbial fermentation innovation to improve production efficiency and product quality [2] Business Strategy - The company is focusing on expanding its domestic and international market presence to boost capacity utilization [2] - Production plans are being arranged based on market demand, ensuring a responsive approach to changing conditions [2] - The company will disclose sales performance of its API business in its annual and semi-annual reports [2]

Core Viewpoint - The animal health sector experienced a slight increase of 0.21% on October 24, with significant contributions from specific stocks, particularly Biological Shares, which led the gains [1] Market Performance - The Shanghai Composite Index closed at 3950.31, up 0.71% - The Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance in Animal Health Sector - Biological Shares (600201) closed at 10.77, up 2.87% with a trading volume of 311,900 shares and a turnover of 333 million yuan - Other notable stocks include: - *ST Green Health (002868): closed at 29.09, up 0.66% - Shunlian Biological (688098): closed at 10.75, up 0.66% - Huisheng Biological (300871): closed at 20.75, up 0.48% - Yongshun Biological (920729): closed at 9.68, up 0.31% - Jinhe Biological (002688): closed at 6.68, unchanged [1] Capital Flow Analysis - The animal health sector saw a net inflow of 8.6031 million yuan from institutional investors, while retail investors experienced a net outflow of 24.4195 million yuan [2] - The breakdown of capital flow indicates: - Repu Biological (300119) had a net inflow of 9.2707 million yuan from institutional investors - Biological Shares (600201) saw a net inflow of 8.4244 million yuan - Kexin Biological (688526) had a net inflow of 5.4428 million yuan from institutional investors [3]

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].

（文章来源：证券日报） 证券日报网讯 10月21日晚间，回盛生物发布公告称，公司及其控股子公司不存在对合并报表外单位提 供担保的情况，无逾期对外担保和涉及诉讼担保的情形。 ...

Core Insights - The article discusses the first batch of bio-manufacturing landmark products announced by Hubei Province's Economic and Information Technology Department on October 9, highlighting significant advancements in the bio-manufacturing sector [2]. Group 1: Landmark Products - The first batch of landmark bio-manufacturing products includes: - Dongyang Sunshine: Thiocyanate Erythromycin - Tianji Bioenergy: Ultra-clean biodiesel - Bafeng Pharmaceutical: Amino acid raw materials - Xinhua Yang: Feed enzyme preparations - Guangji Pharmaceutical: High-quality riboflavin - China National Pharmaceutical Group: Inactivated vaccine for Porcine Circovirus Type 2 - Aibotai Bio: Research antibodies - Huisheng Biotechnology: Tylosin tartrate - Hite Bio-pharmaceutical: Injectable Epinephrine - Fuxing Biotechnology: Arachidonic acid (ARA) powder [2][3]. Group 2: Product Categories - The products are categorized into different types: - Scale Replacement Type: Thiocyanate Erythromycin, Ultra-clean biodiesel, Research antibodies, Tylosin tartrate - Key Improvement Type: Amino acid raw materials, Feed enzyme preparations, High-quality riboflavin, Arachidonic acid powder - Major Innovation Type: Inactivated vaccine for Porcine Circovirus Type 2, Injectable Epinephrine [3].